AI Article Synopsis
- A 27-year-old pregnant woman experienced central retinal vein occlusion during her second pregnancy.
- Investigations indicated that her condition was due to impaired fibrinolysis linked to venous stasis.
- The study highlighted the importance of pregnancy as an additional risk factor, potentially causing complications through changes in blood flow and clotting.
Article Abstract
The authors report the case of 27-year old woman who was 6 months pregnant (second pregnancy, first parity) and presented an occlusion of the central retinal vein. The etiological investigation revealed impaired fibrinolysis after venous stasis. The clinical course including evolution and therapy was stressed. The role of pregnancy as a supplementary risk factor by haemorrheological mechanism was suggested.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Focal choroidal excavation (FCE)-related choroidal neovascular membrane (CNV) in a child.
Retin Cases Brief Rep
June 2024
Department of Ophthalmology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905.
Purpose: To report the rare clinical, optical coherence tomography (OCT), and OCT-angiography findings of a visually significant choroidal neovascular membrane (CNV) in the setting of focal choroidal excavation (FCE) in a child.
Methods: Case report and literature review.
Results: A 9-year-old girl with FCE-related central CNV based on clinical findings and multimodal imaging.
Comparison of ocular posterior segment parameters in the pediatric population with migraine without aura and tension-type headache.
Turk J Pediatr
December 2024
Department of Pediatric Neurology, University of Health Sciences, Kartal Dr. Lütfi Kırdar City Hospital, İstanbul, Türkiye.
Background: This study aims to compare the posterior ocular structure parameters in children with migraine without aura (MWA), tension-type headache (TTH), and a healthy control group.
Methods: The study included 31 patients with MWA, 29 patients with TTH, and 38 healthy controls between 6 and 18 years of age. For all participants, the detailed eye examination and measurements including peripapillary retinal nerve fiber layer (pRNFL) thickness, central macular thickness (CMT), subfoveal choroidal thickness (SCT), macular vessel densities and foveal avascular zone (FAZ) parameters measured by optical coherence tomography (OCT) and OCT-angiography (OCTA), were obtained from the patient files.
Nanotherapy for Neural Retinal Regeneration.
Adv Sci (Weinh)
January 2025
Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology&Visual Sciences Key Lab, Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Key Laboratory of Intelligent Diagnosis, Treatment and Prevention of Blinding Eye Diseases, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China.
Retinal diseases can severely impair vision and even lead to blindness, posing significant threats to both physical and mental health. Physical retinal regenerative therapies are poised to revolutionize the treatment of various disorders associated with blindness. However, these therapies must overcome the challenges posed by the protective inner and outer blood‒retinal barriers.
View Article and Find Full Text PDFRandomised, multicentre, placebo-controlled trial of fenofibrate for treatment of diabetic macular oedema with economic evaluation (FORTE study): study protocol for a randomised control trial.
BMJ Open
December 2024
Westmead Institute for Medical Research, Westmead, New South Wales, Australia
Introduction: Diabetic macular oedema (DMO), a serious ocular complication of diabetic retinopathy (DR), is a leading cause of vision impairment worldwide. If left untreated or inadequately treated, DMO can lead to irreversible vision loss and blindness. Intravitreal injections using antivascular endothelial growth factor (anti-VEGF) and laser are the current standard of treatment for DMO.
View Article and Find Full Text PDFEfficacy & safety of brolucizumab 6.0 mg versus 3.6 mg in diabetic macular edema.
Int J Retina Vitreous
January 2025
Army Hospital Research & Referral, Delhi Cantt, New Delhi, Delhi, 110010, India.
Background: Management of Diabetic Macular edema (DME) requires repeated injections. Therefore newer Anti-VEGFs like Brolucizumab with longer durability have been introduced. We compared two different dosages of Brolucizumab, 6.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!